NewsBenzingaInvivyd And SPEAR Study Group Initiate FLINTLOCK Phase 2 Trial Evaluating Safety, Tolerability, Pharmacokinetics, And Clinical Efficacy Of High-Dose Monoclonal Antibody VYD2311 In Individuals With Long COVID Or Post-Vaccination Syndrome Invivyd And SPEAR Study Group Initiate FLINTLOCK Phase 2 Trial Evaluating Safety, Tolerability, Pharmacokinetics, And Clinical Efficacy Of High-Dose Monoclonal Antibody VYD2311 In Individuals With Long COVID Or Post-Vaccination Syndrome Benzinga 2026.10.14 11:05 (GMT+0) Open on Benzinga Other news Wells Fargo Earnings Aren't Inspiring Enough, But A 7% Income Opportunity Is (NYSE:WFC) Justin Sun trades PEPE again after two years, received 7.2 trillion PEPE from Poloniex multisig address 22 hours ago Martin Marietta: The Lhoist Deal Leaves Little Room For Upside (NYSE:MLM) Lam Research Releases Its Fiscal Q1 Results Next Week - What's the Best LRCX Play? Broadcom Crashed From $495 To $328 - I'm Buying The Sell-Off (NASDAQ:AVGO) MSCI: Growth Near A 5-Year Low Multiple (NYSE:MSCI)
Justin Sun trades PEPE again after two years, received 7.2 trillion PEPE from Poloniex multisig address 22 hours ago
